500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand
Research Use Recombinant Protein Market
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) — The “Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region – Global Forecast to 2031” has been added to ResearchAndMarkets.com’s offering.
Research Use Recombinant Protein Market to Reach USD 1.55 Billion by 2031, Driven by Advanced Therapy Research
The global research use recombinant protein market is projected to grow from USD 1.11 billion in 2026 to USD 1.55 billion by 2031, registering a compound annual growth rate (CAGR) of 7.0% during the forecast period. Market growth is supported by expanding recombinant therapeutic pipelines, increased preclinical research in advanced therapies, and rising demand for recombinant proteins in tumor microenvironment studies.
Cytokines, chemokines, growth factors, antigens, receptors, ligands, and enzymes are increasingly used in drug discovery, immunology, oncology, stem cell research, disease modeling, and cell-based assay development. The shift toward human-expressed recombinant proteins is also improving biological relevance in complex research models.
Ready-to-use liquid formulations and bioengineered heat-stable protein variants offer growth opportunities for automated, high-throughput, and continuous cell culture workflows. However, lot-to-lot variability, inconsistencies in off-the-shelf recombinant proteins, and the high cost of mammalian-expressed products may limit adoption. Non-protein mimics, alternative modalities, and rising supply chain complexity also present challenges for manufacturers and research laboratories.
Human Recombinant Proteins to Record the Highest CAGR
By species, the human segment is expected to register the highest CAGR during the forecast period. Growth is attributed to the expanding use of human-derived proteins in drug discovery, translational research, disease modeling, and advanced cell-based assays. Human cytokines, growth factors, chemokines, receptors, ligands, antigens, and enzymes support research across oncology, immunology, neuroscience, infectious diseases, and stem cell biology.
The adoption of human cell lines, organoids, and physiologically relevant experimental models is further increasing demand for high-purity, biologically active, and application-specific human recombinant proteins.
Cytokines and Chemokines to Lead the Market in 2026
By product, cytokines and chemokines are estimated to account for the largest research use recombinant protein market share in 2026. Their position is supported by extensive use in immunology, oncology, inflammation research, stem cell studies, and drug discovery.
Demand for interleukins, interferons, colony-stimulating factors, and chemotactic proteins continues to rise across organoid development, tumor microenvironment studies, biomarker research, translational applications, cell-based assays, and disease models.
US Market Expected to Register the Highest CAGR
The US research use recombinant protein market is forecast to record the highest CAGR during the forecast period, supported by advanced biomedical research infrastructure, the presence of leading life science companies, and high adoption across drug discovery and preclinical research.
Expanding recombinant therapeutic pipelines and growing research activity in cell and gene therapies, immuno-oncology, stem cell biology, and tumor microenvironment analysis are strengthening US demand. Human-expressed cytokines, growth factors, chemokines, antigens, receptors, and enzymes are increasingly used by pharmaceutical and biotechnology companies, contract research organizations, and academic research institutes.
Competitive Landscape
Key companies offering research use recombinant proteins include Thermo Fisher Scientific Inc. (US), Bio-Techne (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity (US), BPS Bioscience, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sartorius AG (Germany), Sino Biological, Inc. (China), GenScript (China), Proteintech Group, Inc. (US), Miltenyi Biotec (Germany), Enzo Biochem Inc. (US), Abnova Corporation (Taiwan), STEMCELL Technologies (Canada), RayBiotech, Inc. (US), ProSpec-Tany TechnoGene Ltd. (Israel), ProteoGenix (France), Aviva Systems Biology Corporation (US), Elabscience (US), Qkine Ltd. (UK), Abbexa (UK), Bon Opus Biosciences, LLC (US), Novoprotein Scientific Inc. (China), and OriGene Technologies, Inc. (US).
The competitive assessment examines company market shares, product portfolios, growth strategies, new product launches, acquisitions, investments, and recent industry developments. It also evaluates emerging startups operating across the research use recombinant protein ecosystem.
Research Coverage
The report segments the research use recombinant protein market by:
- Product: Cytokines and chemokines, growth factors, recombinant antigens, receptors and ligands, enzymes, ECM and adhesion proteins, and other recombinant proteins
- Formulation: Lyophilized and liquid recombinant proteins
- Species: Human, mouse, rat, non-human primate, and other species
- Host cell: Mammalian, insect, bacterial, yeast and fungi, and other host cells
- Application: Cell culture and differentiation, drug discovery, cancer research, stem cell research, infectious disease and vaccine research, and other applications
- End user: Pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end users
- Region: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
The research analyzes major market drivers, restraints, opportunities, and challenges. It also provides insights into product development and innovation, newly launched products, attractive regional markets, untapped geographies, investments, market diversification, and competitive positioning.
Primary Research Profile
- By respondent: Supply side, 70%; demand side, 30%
- By designation: Managers, 45%; CXOs and directors, 30%; executives, 25%
- By region: North America, 40%; Europe, 25%; Asia Pacific, 25%; Latin America, 5%; Middle East and Africa, 5%
Report Benefits
The report provides revenue estimates for the overall research use recombinant protein market and its subsegments. It enables established companies, new entrants, investors, and other stakeholders to assess the competitive landscape, evaluate market opportunities, strengthen business positioning, and develop informed go-to-market strategies. Detailed coverage of market development, product innovation, regional expansion, competitive activity, and industry risks supports strategic decision-making across the global recombinant protein research ecosystem.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 464 |
| Forecast Period | 2026 – 2031 |
| Estimated Market Value (USD) in 2026 | $1.11 Billion |
| Forecasted Market Value (USD) by 2031 | $1.55 Billion |
| Compound Annual Growth Rate | 7.0% |
Key Topics Covered:
Market Dynamics
- Drivers
- Growing Pipeline for Recombinant Therapeutic Proteins
- Rising Preclinical Research in Advanced Therapies (Cell & Gene Therapies)
- Shift Toward Human-Expressed Recombinant Proteins for Ruo Applications
- Rising Demand for Ruo Recombinant Proteins in Tumor Microenvironment Studies
- Challenges
- Restraints
- High Lot-to-Lot Variability and Inconsistency in Off-the-Shelf Recombinant Proteins for Research-Use Applications
- High Costs Associated With Premium Recombinant Proteins Expressed in Mammalian Cells
- Advent of Non-Protein Mimics and Alternative Modalities
- Rising Supply Chain Complexities
- Restraints
- Case Studies
- Recombinant Ligand Screening Maps Inflamed Intestinal Organoid Responses
- Recombinant Osteoglycin Supports Alveolar Organoid Research
- Recombinant Antigens Improve H. Pylori Assay Development
- Industry Trends
- Trends/Disruptions Impacting Customers’ Businesses
- Opportunities
- Emergence of Ready-to-Use Liquid Formulations for Integration Into Automated High-Throughput Workflows
- Development of Bioengineered, Heat-Stable Protein Variants for Continuous Cell Lines & Cell Culture
Company Profiles
- Thermo Fisher Scientific Inc.
- Merck Kgaa
- Bio-Techne
- Danaher Corporation
- Revvity
- Bio-Rad Laboratories, Inc.
- Bps Bioscience, Inc.
- Sartorius AG
- Sino Biological, Inc.
- Genscript
- Proteintech Group, Inc.
- Miltenyi Biotec
- Enzo Biochem, Inc.
- Abnova Corporation
- Stemcell Technologies
- Raybiotech, Inc.
- Prospec-Tany Technogene Ltd.
- Proteogenix
- Aviva Systems Biology Corporation
- Elabscience
- Qkine Ltd.
- Abbexa
- Bon Opus Biosciences, LLC
- Novoprotein Scientific Inc.
- Origene Technologies, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/gwsrqp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Research Use Recombinant Protein Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
